Business development

Cantargia’s business model is based on partnerships, and Cantargia has entered agreements with a number of companies, hospitals and academic groups. Currently, around 50 international and local players are engaged in research and development related to Cantargia’s nadunolimab (CAN04) project.

We are now building partnerships in a similar way in our new project, CAN10.